Bristol Myers Squibb Company $BMY Stock: XXI Wealth LLC Raises Stake

XXI Wealth LLC increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 87.4% in the third quarter, Holdings Channel reports. The institutional investor owned 30,096 shares of the biopharmaceutical company’s stock after acquiring an additional 14,039 shares during the period. XXI Wealth LLC’s holdings in Bristol Myers Squibb were worth $1,878,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Davis Asset Management L.P. bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth about $27,000. Addison Advisors LLC bought a new position in Bristol Myers Squibb during the 2nd quarter valued at about $32,000. Groupe la Francaise grew its holdings in Bristol Myers Squibb by 562.9% during the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 501 shares during the last quarter. Kilter Group LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter worth about $35,000. Finally, Arlington Trust Co LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter worth about $35,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers and SystImmune reported that izalontamab brengitecan reduced the risk of disease progression or death by 59% versus chemotherapy in the Phase 3 PANKU-Breast01 trial for advanced HR-positive/HER2-negative breast cancer. The result could strengthen BMY’s oncology pipeline and support a future regulatory filing. Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
• Positive Sentiment: BMY expanded its multi-year collaboration with Tempus AI, licensing multimodal oncology data through 2031 to aid target discovery and drug development. Separately, BMS is collaborating with Pathos AI and Tempus on AI-driven research in Alzheimer’s disease and other neurological conditions, while leading Pathos’s Series E financing and gaining access to its Foundry platform. These deals may improve research productivity and pipeline potential, although financial benefits are longer term. Tempus Expands Strategic Collaboration with Bristol Myers Squibb Pathos AI Announces Strategic Collaborations
• Positive Sentiment: Analyst H. Engel modestly raised Erste Group’s FY2027 EPS forecast to $6.56 from $6.53, matching consensus and suggesting stable expectations for BMY’s earnings power. Bristol Myers Squibb analyst estimate update
• Neutral Sentiment: Phase 1 Breakfree-2 data for the CAR-T therapy zolacabtagene autoleucel in highly active multiple sclerosis provide another pipeline catalyst, but the early-stage study still requires larger and later-stage testing before its commercial value can be assessed. Bristol Myers Squibb Presents Breakfree-2 Results
• Negative Sentiment: Bristol Myers disclosed a patient death in the early-stage cell-therapy study. Even if the event does not ultimately change the program’s development, it introduces a safety overhang and may overshadow the positive efficacy data. Bristol Myers discloses patient death in early-stage cell therapy study
• Negative Sentiment: Pre-earnings coverage anticipates a year-over-year decline in third-quarter earnings, keeping attention on legacy-drug erosion, pipeline execution and BMY’s relatively high debt load. These concerns could outweigh the company’s inexpensive valuation and attractive dividend in the near term. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline

Analyst Ratings Changes

Several analysts have issued reports on the stock. Leerink Partners downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $73.00 to $59.00 in a research note on Monday, October 5th. Morgan Stanley reaffirmed an “underweight” rating and set a $41.00 target price (up from $40.00) on shares of Bristol Myers Squibb in a research note on Wednesday, October 7th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. JPMorgan Chase & Co. increased their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Finally, Daiwa Securities Group raised their price target on Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average price target of $64.88.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Trading Down 2.3%

Shares of NYSE BMY traded down $1.42 during mid-day trading on Friday, reaching $61.58. The company had a trading volume of 9,762,895 shares, compared to its average volume of 13,420,046. The stock has a market cap of $125.79 billion, a price-to-earnings ratio of 13.56, a price-to-earnings-growth ratio of 0.32 and a beta of 0.19. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The business’s 50-day moving average is $63.26 and its 200-day moving average is $60.33. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same quarter last year, the business posted $1.46 EPS. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.56 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.